Lung Squamous Cell Carcinoma — Trials

Lung Squamous Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

141 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 37
Recruiting: 19
Ph III recruiting: 1
Growth YoY: —
Industry share: 46%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05718167	TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.	unknown	Phase 3	570	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY	1	Feb 14, 2023	clinicaltrials
NCT01947062	Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma	unknown	Phase 3	60	Swami Rama Cancer Hospital and Research InstituteINDUSTRY